Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Publicly Traded Israeli Cannabis Stocks Rally 20,000%

Feb 22, 2017 • 11:25 AM EST
4 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

In early 2015, we highlighted three publicly traded Israeli cannabis companies to watch and we hope you listened!

Although Canadian cannabis stocks have been the story to watch over the last year, Israeli cannabis stocks have been stealing headlines in 2017.  

This comes after two United States traded Israeli cannabis companies, Cannabics Pharmaceuticals (CNBX) and OWC Pharmaceutical Research (OWCP) rallied 842% and 1087%, respectively so far this year.

Despite our bullish view on CNBX and OWCP prior to this rally, we have not seen anything to justify a rally of this magnitude and are cautious at current levels.

What Drives a 19,000% Rally in Less Than Six Months?

Since October 3rd, Cannabics Pharmaceuticals (CNBX) and OWC Pharmaceutical Research (OWCP) have rallied 13,594% and 19,251%.

On October 3, 2016, CNBX traded for less than $0.05 while OWCP traded for less than $0.01. CNBX and OWCP are currently trading at $6.45 and $2.09, respectively.

Although these rallies are tremendous, we think the shares are overvalued and do not think these prices are sustainable in the near term. 

What do these Companies Do?

Cannabics Pharmaceuticals, a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The company’s leading product is Cannabics SR, a long acting medical cannabis capsule designed for cancer patients as a palliative treatment. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The company’s focus is on harnessing the therapeutic properties of natural cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.

One World Cannabis, founded in 2014, is an Israeli company focused on the research and development of cannabis-based pharmaceuticals and treatments focused on a wide variety of medical issues. Through its Israeli based fully owned subsidiary, the company is a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders. In November, OWCP announced that it was submitting the safety protocol for its psoriasis cream to Israel’s national Institutional Review Board. The study is currently underway and the results are expected by the end of March, 2017.

Urge Caution, Be Selective

We urge caution with investing in companies like this. The charts look very similar to Pineapple Express (PNPL) before it was suspended by FINRA as well as AXIM Biotech (AXIM), which has fallen more than 50% from its recent highs.

Focus on quality companies that are not overvalued and are led by a management team with a proven track record of success.  


Important Investor Disclosures 

Disclosure.  Compensated Affiliate.  This report was authored by and is property of StoneBridge Partners LLC.  All information and data relied upon in drafting this report is publicly available.  The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report.  Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice.  Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results.  None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment.  This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation.  The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals.  It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction.  Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks.  The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission.  Please contact a Financial Advisor for professional advice regarding any and all securities investments.  This report is intended for informational purposes only.  StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC.  StoneBridge Partners LLC receives compensation from the company and/or has a position in the securities mentioned in this report

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.